¥ 489
%E4%BC%98%E9%80%89%E7%9B%B4%E6%92%AD%E5%B9%B3%E5%8F%B02024%E6%9C%80%E6%96%B0%E7%89%88%E5%8A%9F%E8%83%BD%E4%BB%8B%E7%BB%8D 芳拓生物宣布其自主研发的面向XLRP的重组腺相关病毒(rAAV)基因治疗产品FT-002注射液获得FDA II期临床试验许可
¥ 464
¥ 998
¥ 440